Key result
Intracranial neoplasms were associated with almost six times higher plasma tissue factor activity compared to noncancer controls, indicating a higher prothrombotic risk.
Why the study?
The study was conducted to investigate the concentration and activity of TF and TFPI, along with TAT complexes, in patients with primary and metastatic intracranial neoplasms.
Are tissue factor and related coagulation biomarkers elevated in patients with intracranial neoplasms compared to controls?
Case-Control (n=99)
Are tissue factor and related coagulation biomarkers elevated in patients with intracranial neoplasms compared to controls?
Patients with intracranial neoplasms exhibit high concentration and activity of tissue factor and low tissue factor pathway inhibitor, indicating a higher prothrombotic risk.
Answers are grounded in this paper and cite their sources.
Supports TF activity consideration in intracranial neoplasm thrombosis risk assessment; leaves open prospective validation before clinical adoption.
The aim of the study was to investigate the concentration and activity of tissue factor (TF) and Tissue factor pathway inhibitor (TFPI) as well as the concentration of thrombin-antithrombin (TAT) complexes in patients with primary and metastatic intracranial neoplasms. The study included 69 patients with an average age of 62 years. Twenty-one patients were diagnosed with gliomas, 18 meningioma stage II (M) patients, and 30 metastatic brain tumour cases (Meta). The control group consisted of 30 individuals with a mean age of 57 years. In the plasma of all the participants and in tumour tissue-derived homogenate, the concentrations and activities of TF, TFPI, the concentration of TAT complexes and the concentration of total protein were measured. The results were converted per 1 mg of protein. The concentration of TF was over 80 times higher in the tumour tissue-derived homogenate in respect to patients' plasma levels. Plasma TF activity in intracranial cancer patients was almost six times higher compared with noncancer counterparts, while in the tumour tissue-derived homogenate it was more than 14 times higher than in the intracranial cancer patients' plasma, whereas the concentration of TFPI in the tumour tissue-derived homogenate was significantly lower than in the patients' plasma. However, a significantly higher TFPI activity in the tumour tissue derived than in the patients' plasma was reported. The high concentration and activity of TF, along with the coexisting low concentration and activity of TFPI in the plasma of intracranial tumour patients, is associated with a higher prothrombotic risk in these patients.
No takes yet. Share an insight, caveat, or question.
Bierwagen et al. (2022) conducted a case-control in Primary and metastatic intracranial neoplasms (n=99). Primary and metastatic intracranial neoplasms vs. Noncancer controls was evaluated on Concentration and activity of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and thrombin-antithrombin (TAT) complexes. Intracranial neoplasms were associated with almost six times higher plasma tissue factor activity compared to noncancer controls, indicating a higher prothrombotic risk.
Synapse has enriched 10 related papers. Consider them for comparative context: